English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/200643
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Targeting of replicating CD133 and OCT4/SOX2 expressing glioma stem cells selects a cell population that reinitiates tumors upon release of therapeutic pressure

AuthorsGuerra-Rebollo, Marta; Garrido, Cristina; Sánchez-Cid, Lourdes; Soler-Botija, Carolina; Meca-Cortés, Óscar ; Rubio, Núria ; Blanco, Jerónimo
KeywordsNeoplastic Stem Cells
Glioblastoma stem
Issue Date1-Dec-2019
PublisherSpringer Nature
CitationScientific Reports 9 (1): 9549 (2019)
AbstractThe existence of radio- and chemotherapy-surviving cancer stem cells is currently believed to explain the inefficacy of anti-glioblastoma (GBM) therapies. The aim of this study was to determine if a therapeutic strategy specifically targeting GBM stem cells (GSC) would completely eradicate a GBM tumor. In both the in vitro and the in vivo models, ganciclovir therapy targeting proliferating GSC promotes the survival of a quiescent, stem-like cell pool capable of reproducing the tumor upon release of the therapeutic pressure. Images of small niches of therapy-surviving tumor cells show organized networks of vascular-like structures formed by tumor cells expressing CD133 or OCT4/SOX2. These results prompted the investigation of tumor cells differentiated to endothelial and pericytic lineages as a potential reservoir of tumor-initiating capacity. Isolated tumor cells with pericyte and endothelial cell lineage characteristics, grown under tumorsphere forming conditions and were able to reproduce tumors after implantation in mice. © 2019, The Author(s).
Publisher version (URL)https://doi.org/10.1038/s41598-019-46014-0
Appears in Collections:(IQAC) Artículos
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.